{"name":"Taysha Gene Therapies, Inc.","slug":"taysha","ticker":"TSHA","exchange":"NASDAQ","domain":"tayshagtx.com","description":"Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.","hq":"Dallas, TX","founded":0,"employees":"99","ceo":"Sean Nolan","sector":"Biotech","stockPrice":6.38,"stockChange":-0.29,"stockChangePercent":-4.35,"marketCap":"$1.8B","metrics":{"revenue":7471000,"revenueGrowth":0,"grossMargin":100,"rdSpend":0,"netIncome":-129876000,"cash":276576000,"dividendYield":0,"peRatio":-14,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"TSHA-101 patent cliff ($0.0B at risk)","drug":"TSHA-101","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"TSHA-201 patent cliff ($0.0B at risk)","drug":"TSHA-201","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Taysha Gene Therapies Announces FDA Clearance of Investigational New Drug (IND) Application for TSHA-101","summary":"Taysha Gene Therapies announced that the FDA has cleared the IND application for TSHA-101, enabling the company to proceed with clinical trials.","drugName":"TSHA-101","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Taysha Gene Therapies Reports Third Quarter 2023 Financial Results","summary":"Taysha Gene Therapies reported its third-quarter 2023 financial results, highlighting progress in its pipeline and operational efficiency.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Taysha Gene Therapies Announces Collaboration with the University of Texas Southwestern Medical Center","summary":"Taysha Gene Therapies announced a collaboration with the University of Texas Southwestern Medical Center to advance gene therapies for CNS disorders.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-02","type":"regulatory","source":"simplywall.st","summary":"Taysha Gene Therapies (TSHA) Valuation Review After TSHA-102 REVEAL Trial And FDA Alignment Progress - simplywall.st","headline":"Taysha Gene Therapies (TSHA) Valuation Review After TSHA-102 REVEAL Trial And FDA Alignment Progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNTTBvMWg0N3RBT3A3RjZmdzVGQzhoUll5eFlGM0VNdjJCeGFkZ2x1WGVwNGw1QmJOYjF1bzZRZGtIRUhnQXFTeXgwUk5odVVmcXpseEVEOHhSajRWLUZnNExNU09hZWFNQVl1X2wyNDZUM2JNU0lrZDNsZzJMTkZhb3lPdXpXY05VM0RN?oc=5","date":"2026-01-29","type":"pipeline","source":"Yahoo Finance","summary":"Here’s What Analysts Are Saying About Taysha Gene Therapies (TSHA) - Yahoo Finance","headline":"Here’s What Analysts Are Saying About Taysha Gene Therapies (TSHA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxNT2EwVDA1QTljMDViWTJzbXk0T181bThWYlgtN2preGFOVWk0Vk1sQk9qQzlna2xrcEVjaUNhX3U2LUZ3cnRsRVBDZjdoWmo0TTFWb2dGX1JtUmQ3aUUyOGxsa1VBcU5IaXhwUU0wWGJsZnllaU52TlNrNHhoMXJNSDlQLXpGNUxJWFNhZzAxcXVFalBVWk84WlJLRXNuYS1CbGhVc0tKMzd4cUY0b2VmdngyR0xMeEJacUVCNldNYlh0azI5TDJWX2FOczNCeUJYMkY0WE5wemJDNDNxbmFCb1FKVkIwMFVodExtdV9lZWg1Qm5t?oc=5","date":"2025-10-20","type":"regulatory","source":"Benzinga","summary":"Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga","headline":"Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPbzVsZHJhRnpGRGt2RXlNT0l1ZWladnZ1QWNUSjFLb3pZa3JKREtGQXF5UE9kVmVzNi1TM01hNjQ5UU5KSG9fUXFmRmloWVJBdmdrZ0hCeGVTTkZXWms0WWZyOVNzNVBQeGxNeUtkT2lUQXlvWHByX0ttRkFFNXFWOVd5enR0bnYxQTlqOWFjV0ZMLS1ES0tSaXZiMU9GT1NkVklNSTN4eVg?oc=5","date":"2025-10-17","type":"patent","source":"bioworld.com","summary":"Bring it back home: Taysha regains gene therapy as option expires - bioworld.com","headline":"Bring it back home: Taysha regains gene therapy as option expires","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPb2o4S3FueFNlMld2S1IyWmlsaThVWGs4M1lISEpMSjBzTEJTWFE0SW5LcElzU29fUk5zeXdyZHNKSW5fVjllbmphN3gxeFFqTFM2aVhxV1BnRjY4Sm1MbEw3N3ZzYWVpak1JUWNPYVJWajlmMVpCN1B4YkNXMXNuRTBjLV9VanFldWhNZQ?oc=5","date":"2025-10-08","type":"pipeline","source":"Yahoo Finance","summary":"Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory - Yahoo Finance","headline":"Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOZ0FUYmlPZnVkRDhjY29UT0kyenhuTzF2TXFLWTlRMDQ2RTdrVFZUM1E2cVpCQWZ1WjZCSE13eGJXX3FubnBxa3BVMXEtOC13THpLdTY1cXYxRkpnMDJ1bDdpSktJRGlnMlAzalA5aHdrZHN6by1ZUWU1bDdjSEZMOTZNTFFsQjhsRnMtb0Z4NmJIeDk0cENjM0Rab0hJVnhwdVBJeUpZTzhEXzJjbER3blN0SXI?oc=5","date":"2025-10-02","type":"regulatory","source":"Seeking Alpha","summary":"Taysha Gene Therapies: Shares Are Soaring On FDA Alignment, But Caution Is Advised - Seeking Alpha","headline":"Taysha Gene Therapies: Shares Are Soaring On FDA Alignment, But Caution Is Advised","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOTXIxMnJiUnY0TTRLUUREZUlZdk81MDd0dUNPaWRjbVZuclI4eHhBZ18td2JUU0lTQkxYc1lpb2UwRmlGenNBZmN4SXNlSHZOa3ViU2FQZ0ctUGRfSUowd3pNNGpyVzF5N05KbTVkNHM3ZzNYOHFzcURjcGtfX1o5bGd0UVJkSjc5NmhlejluZmd3VmdNV2lOSGVKa1ZtU1dYMzhhZTZhY0t2TldscEh6RmFQenFiLURKTnJZbUdqeEhBaHFYaFV1X0dR?oc=5","date":"2025-04-15","type":"pipeline","source":"Seeking Alpha","summary":"Taysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited Opportunity - Seeking Alpha","headline":"Taysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited Opportunity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPREpWQmR1NEN3NnlUS3pVUGpISHFrSHRCSng5MjlmV3B1c0pjM1UyeXNBUDM5enZsNUpwMXhKYld0OGtaeC1SZGlSZjBXR3RWLWU5LUt0VFM5LXFfQXNQbU1ONU9FWkpoSkJJYUNnREdXMFVocy1LaElyT2RBeWwwVUJRSkdmZkJUSnJQak5ZZldlbUVkV184VlFFcGdEVWphejFIUTNXX0JncmtHcS1BU3N3Y0hmNTRubloxNDBjdWdMT2lqWFl5Zk5LeXI?oc=5","date":"2024-06-26","type":"pipeline","source":"2 Minute Medicine","summary":"Taysha Gene Therapies: TSHA-102 Gene Therapy Improves Quality of Life in Patients with Rett Syndrome - 2 Minute Medicine","headline":"Taysha Gene Therapies: TSHA-102 Gene Therapy Improves Quality of Life in Patients with Rett Syndrome - 2 Minute Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE91T3FBWnJnOGNQVzBmLTVoQXFJcFVVd2dPWElwLUgwYVRENHp5bWVOWHFFX091Z1RHR1V2cUx0YUFHaVowaXplQjBkTmZmaDBS?oc=5","date":"2024-03-20","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOU0R2RWpGcTNBeUpwTkJKcFFMUDJBdzFnYzFhOEdSOWdIbHo0OFQ4ZVF3VElSTHVVdTJROEpOYzJha09EUlRoZktCUlprWU5sWm9EdkFpVDRDTmlDOUtMZUxhRnVzczdFaS1jQXp1RTBQVFduTktBSGJnMUtCbVg0NG41Z1pvSXBu?oc=5","date":"2023-09-20","type":"regulatory","source":"BioPharma Dive","summary":"Taysha drops lead gene therapy following FDA feedback - BioPharma Dive","headline":"Taysha drops lead gene therapy following FDA feedback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxObXlBbG1TUF9oRnFJU3o4M1NadUtSMWtXVUYyRWxaTW5MUGNweXV4ZXdRMkdjVFJhNWk1Ukp2eUpab2d2TXdFNXRtcDc1dUlyLTg3SDJTUkh4UEZVT1UyWXRmWEtKYzNWSHRRSXgtR3FhdDNVNUFRN1VlTlhNT1prb0RUTDB3M0lr?oc=5","date":"2022-12-19","type":"pipeline","source":"dallasinnovates.com","summary":"Taysha Gene Therapies Replaces CEO, Appoints R&D Chief - dallasinnovates.com","headline":"Taysha Gene Therapies Replaces CEO, Appoints R&D Chief","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxNaW5pVTBBYVpHYjNLa1JuTEdSWkkyRHh2MVh1R3JDdXlFV1JST2Rhd0U5WTVqWnQxTFRBRGxSTmNHckg5aG9KQ3VKZ2RlZ3BmZmFwcm9ub2poZVNwaFBtWENrbkZkUzkzWXN1TUZ3QjJUaHZRTkxoNGpqQjZhR0xwbnJ6MjQtRTUxV012dVFBdXlMaGdLancwVXJySVlNWXFQWUNKQm9JNGZUZW52UEppeXF0UGM0aklDQmdsWmpKUkRxS00wMkY2M2lnVWl5V1ZyRnV2aTdWZ19WbXVpWTRqa2lKQXgtT254Q1lKaHMxTGg5REsxQ21QNUxvZkJhU1JPVDBTbmZFQ015OVl0akF1VE45R1Y?oc=5","date":"2022-10-24","type":"pipeline","source":"PR Newswire","summary":"Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs - PR Newswire","headline":"Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Thera","sentiment":"neutral"}],"patents":[{"drugName":"TSHA-101","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"TSHA-201","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sarepta Therapeutics","BioMarin Pharmaceutical","Pfizer"],"therapeuticFocus":["Central Nervous System (CNS) Disorders"],"financials":{"source":"yahoo_finance","revenue":9773000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":9773000},{"period":"2024-12-31","value":8333000},{"period":"2023-12-31","value":15451000},{"period":"2022-12-31","value":2502000}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":86403000,"rdSpendHistory":[{"period":"2025-12-31","value":86403000},{"period":"2024-12-31","value":66001000},{"period":"2023-12-31","value":56778000},{"period":"2022-12-31","value":91169000}],"sgaSpend":33868000,"operatingIncome":-110498000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-110498000},{"period":"2024-12-31","value":-86621000},{"period":"2023-12-31","value":-71374000},{"period":"2022-12-31","value":-126027000}],"netIncome":-108995000,"netIncomeHistory":[{"period":"2025-12-31","value":-108995000},{"period":"2024-12-31","value":-89298000},{"period":"2023-12-31","value":-111566000},{"period":"2022-12-31","value":-166014000}],"eps":-0.36,"epsHistory":[{"period":"2024-12-31","value":-0.36},{"period":"2023-12-31","value":-0.96},{"period":"2022-12-31","value":-3.78},{"period":"2021-12-31","value":-4.64}],"cash":319767000,"cashHistory":[{"period":"2025-12-31","value":319767000},{"period":"2024-12-31","value":139036000},{"period":"2023-12-31","value":143940000},{"period":"2022-12-31","value":87880000}],"totalAssets":343320000,"totalLiabilities":96382000,"totalDebt":70143000,"equity":246938000,"operatingCashflow":-93090000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-93090000},{"period":"2024-12-31","value":-81225000},{"period":"2023-12-31","value":-73018000},{"period":"2022-12-31","value":-88390000}],"capex":-738000,"capexHistory":[{"period":"2025-12-31","value":-738000},{"period":"2024-12-31","value":-374000},{"period":"2023-12-31","value":-7369000},{"period":"2022-12-31","value":-24869000}],"freeCashflow":-93828000,"dividendsPaid":null,"buybacks":null,"employees":99,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":8833000,"ebit":-27839000,"ebitda":-27540000,"period":"2025-12-31","revenue":5485000,"epsBasic":null,"netIncome":-27851000,"rdExpense":24952000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-28300000},{"sga":8279000,"ebit":-32718000,"ebitda":-32432000,"period":"2025-09-30","revenue":0,"epsBasic":-0.09,"netIncome":-32733000,"rdExpense":25745000,"epsDiluted":-0.09,"grossProfit":null,"operatingIncome":-34024000},{"sga":8598000,"ebit":-26865000,"ebitda":-26588000,"period":"2025-06-30","revenue":1986000,"epsBasic":-0.09,"netIncome":-26882000,"rdExpense":20141000,"epsDiluted":-0.09,"grossProfit":null,"operatingIncome":-26753000},{"sga":8158000,"ebit":-21510000,"ebitda":-21227000,"period":"2025-03-31","revenue":2302000,"epsBasic":-0.08,"netIncome":-21529000,"rdExpense":15565000,"epsDiluted":-0.08,"grossProfit":null,"operatingIncome":-21421000},{"sga":6629000,"ebit":-18763000,"ebitda":-18459000,"period":"2024-12-31","revenue":2022000,"epsBasic":null,"netIncome":-18785000,"rdExpense":15325000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-19932000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.1,"netIncome":null,"rdExpense":null,"epsDiluted":-0.1,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":6.38,"previousClose":6.67,"fiftyTwoWeekHigh":7.3,"fiftyTwoWeekLow":2.25,"fiftyTwoWeekRange":"2.25 - 7.3","fiftyDayAverage":5.33,"twoHundredDayAverage":4.52,"beta":1.23,"enterpriseValue":1708673024,"forwardPE":-14,"priceToBook":7.37,"priceToSales":245.59,"enterpriseToRevenue":228.71,"enterpriseToEbitda":-13,"pegRatio":0,"ebitda":-131406000,"ebitdaMargin":0,"freeCashflow":-73448000,"operatingCashflow":-111948000,"totalDebt":68551000,"debtToEquity":32.3,"currentRatio":14.04,"returnOnAssets":-37.8,"returnOnEquity":-97.3,"analystRating":"1.2 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":14,"targetMeanPrice":11.86,"targetHighPrice":19,"targetLowPrice":7,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":10.6,"institutionHeldPercent":95,"sharesOutstanding":287361020,"floatShares":198557844,"sharesShort":40051105,"shortRatio":14.1,"shortPercentOfFloat":13.9,"epsTrailing":-0.38,"epsForward":-0.46,"revenuePerShare":0.02,"bookValue":0.87,"officers":[{"age":57,"name":"Mr. Sean P. Nolan","title":"CEO & Chairman"},{"age":58,"name":"Dr. Sukumar  Nagendran M.D.","title":"President, Head of Research & Development and Director"},{"age":47,"name":"Mr. Kamran  Alam CPA, M.B.A.","title":"CFO & Corporate Secretary"},{"age":null,"name":"Hayleigh  Collins","title":"Director of Corporate Communications & Investor Relations"},{"age":null,"name":"Mr. Frederick  Porter Ph.D.","title":"Chief of Staff & Technical Operations Officer"},{"age":null,"name":"Ms. Emily  McGinnis M.P.H.","title":"Chief Patient & External Affairs Officer"},{"age":null,"name":"Mr. Sean  McAuliffe","title":"Chief Business Officer"},{"age":null,"name":"Dr. Steven  Gray Ph.D.","title":"Chief Scientific Advisor of UT Southwestern Gene Therapy Program"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.tayshagtx.com","phone":"214 612 0000"}}